Search results
Results from the WOW.Com Content Network
The length of peritoneal dialysis treatment appears to be the primary risk factor for encapsulating peritoneal sclerosis development. The incidence of encapsulating peritoneal sclerosis rose with the length of peritoneal dialysis (PD) in an Australian survey; for patients on PD for more than 2, 5, 6, and 8 years, the rates were 1.9, 6.4, 10.8 ...
Particularly hazardous is the downward traction of the phrenicocolic ligament (this maneuver may be necessary for the mobilization of splenic flexure). [ citation needed ] This ligament marks the site where the colon exits the peritoneal cavity: the phrenicocolic ligament is thus an important point of intersection of abdominal anatomy and ...
Peritoneal ligaments are folds of peritoneum that are used to connect viscera to viscera or the abdominal wall. There are multiple named ligaments that usually are ...
Ligamentous laxity or ligament laxity can appear in a variety of ways and levels of severity. In most people, ligaments (which are the tissues that connect bones to each other) are naturally tight in such a way that the joints are restricted to 'normal' ranges of motion. This creates normal joint stability.
Visceroptosis is a known risk factor for the development of Superior mesenteric artery syndrome. Visceroptosis also is known as Glénard's disease (after French physician Frantz Glénard [1848–1920]). Glénard's theory – the theory that abdominal ptosis is a nutritional disease with atrophy and prolapse of the intestine
Treatment often includes antibiotics, intravenous fluids, pain medication, and surgery. [3] [4] Other measures may include a nasogastric tube or blood transfusion. [4] Without treatment death may occur within a few days. [4] About 20% of people with cirrhosis who are hospitalized have peritonitis. [1]
Intraperitoneal injection or IP injection is the injection of a substance into the peritoneum (body cavity). It is more often applied to non-human animals than to humans. In general, it is preferred when large amounts of blood replacement fluids are needed or when low blood pressure or other problems prevent the use of a suitable blood vessel for intravenous injection.
Imipenem/cilastatin is indicated for the treatment of severe or complicated skin, tissue, joint, respiratory tract, intra-abdominal, urinary tract and urogenital infections, but not meningitis (as it does not pass through the blood brain barrier), endocarditis, and sepsis due to susceptible organisms.